After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA

Executive Summary: Ireland's Once-in-a-Generation Corridor Moment

Two events have redrawn the map for Irish life sciences within twelve months. On January 27, 2026, the European Union and India concluded their Free Trade Agreement in New Delhi after nearly two decades of negotiation, a pact European Commission President Ursula von der Leyen called the "mother of all deals," covering a combined market of two billion consumers. On July 15, 2026, the UK-India CETA entered into force next door, giving British pharma a one-year head start on tariff-free access to the Indian market.

Ireland cannot sign its own trade agreement with India. Trade policy is an exclusive EU competence. But that constraint hides an opportunity: the heavy lifting on tariffs and market access has already been done in Brussels, and the differentiating layer—the regulatory bridges, investment pipelines, research compacts and talent corridors that turn an FTA into an actual corridor—is entirely within Dublin's and New Delhi's control. This report sets out what that Ireland-India life sciences architecture should look like, models what it could deliver by 2030, and closes with concrete recommendations for the Irish Government, the IDA, the HPRA, Research Ireland, and their Indian counterparts.

The headline finding of our modelling: a deliberately built corridor could lift Ireland-India bilateral trade from €17.7 billion in 2024 to approximately €31 billion by 2030, roughly €5 billion above the passive baseline, while de-risking both economies at their single most exposed points: Ireland's dependence on the US market, and Europe's dependence on concentrated API supply.

Section 1: The Window Opens: From UK-India CETA to the EU-India FTA

The EU-India FTA was concluded at the 16th EU-India Summit at Hyderabad House, New Delhi, capping negotiations first launched in 2007, suspended in 2013, and relaunched in 2022. The scale is unprecedented for both sides. The EU and India already exchange more than €180 billion in goods and services annually, supporting close to 800,000 jobs across the EU, and India's goods trade with the bloc reached USD 136.5 billion in FY2024-25.

The tariff architecture matters enormously for life sciences. India will progressively eliminate or reduce duties on 96.6% of EU export lines, including pharmaceuticals, which currently face duties of around 11%, and chemicals, which face duties of up to 22%. The EU liberalises 99.3% of lines for Indian goods, cementing duty-free access for Indian formulations, biosimilars and APIs into the single market. Beyond tariffs, the concluded package includes a framework to negotiate Social Security Agreements over a five-year horizon, provisions supporting student mobility and post-study work, and cooperation on technical barriers to trade designed to make regulatory processes more transparent and predictable.

The agreement is not yet law. Legal scrubbing of the text was completing in July 2026, with signature expected by the end of 2026 and entry into force targeted for the first half of 2027, a timeline reaffirmed at the third EU-India Trade and Technology Council in Brussels this month. India's Commerce Minister Piyush Goyal has described it as likely to be the fastest trade agreement ever approved in the EU. Two companion instruments, the Investment Protection Agreement and the Geographical Indications Agreement, remain under negotiation.

For Ireland, the reference point is the UK's parallel track. The UK-India CETA, signed July 24, 2025, and in force since July 15, 2026, eliminated duties on 56 pharmaceutical tariff lines, established GMP mutual recognition between the MHRA and CDSCO, and delivered a Double Contributions Convention exempting posted professionals from dual social security payments for up to five years. Our deep dive into the CETA pharmaceutical value chains analysed how those provisions restructure the UK-India axis. Every one of those mechanisms is a template, and a competitive benchmark, for what the Ireland-India corridor must now match through the EU framework and bilateral instruments.

Section 2: Why Ireland Cannot Sign Its Own FTA, and Why That Is an Advantage

A necessary clarification, because it is the most misunderstood point in this debate: under the EU treaties, common commercial policy, including tariffs and trade agreements, is an exclusive competence of the Union. There will never be a standalone "Ireland-India Free Trade Agreement." Any analysis that proposes one is proposing something legally impossible.

What Ireland can do sits in three layers. First, shape the EU position: as a member state, Ireland votes in the Council on signature and conclusion of the FTA, and Irish MEPs vote on the European Parliament's consent. Ireland's EU Council Presidency in the second half of 2026 places Dublin in the chair precisely when the FTA moves through signature, an extraordinary piece of timing that should be used deliberately. Second, build the bilateral layer beneath the FTA: memoranda of understanding, regulatory cooperation arrangements, research funding compacts, investment promotion agreements and talent frameworks are all within national competence. The India-Ireland Joint Economic Commission, agreed during External Affairs Minister S. Jaishankar's Dublin visit in March 2025, is the natural chassis for this layer. Third, compete for the corridor's physical footprint: FTAs open markets for all 27 member states equally, but manufacturing plants, global capability centres, clinical trial networks and R&D partnerships land in specific countries. That competition has already begun, and it is winner-takes-most.

The advantage of this structure is speed and focus. Ireland does not need to negotiate tariff schedules; Brussels has done it. Every unit of Irish diplomatic and agency effort can go into the layer where Ireland actually differentiates: regulation, talent, research and investment facilitation.

Section 3: Two Complementary Powerhouses

The industrial logic of an Ireland-India corridor is not similarity but complementarity, the same logic that underpinned the UK-India deal, with Ireland holding several cards the UK no longer does: EU membership, EMA jurisdiction, and frictionless access to the single market of 450 million people.

Ireland is the concentrated high-value node. Pharmaceutical exports reached €139 billion in 2025, representing 53% of all Irish goods exports and 41% of modified GNI, with roughly 75,000 people employed in pharma manufacturing and related activities. Nine of the world's ten largest pharmaceutical companies and 14 of the top 15 medtech companies operate Irish sites, across more than 90 pharmaceutical operations. Ireland ranks as the world's third-largest pharmaceutical exporter, built on biologics, high-potency small molecules, fill-finish and advanced medtech.

India is the scale and resilience node. Pharmaceutical exports reached USD 30.4 billion in FY2025, growing 9.4% year on year, from an industrial base of more than 3,000 companies and 10,500 manufacturing units. India supplies around 20% of global generic medicines by volume and roughly 60% of global vaccine demand, operates the largest network of US FDA-approved plants outside the United States, and is targeting a domestic market of USD 120-130 billion by 2030, with the Bain-Pharmexcil roadmap projecting exports of USD 350 billion by 2047. Government production-linked incentive (PLI) schemes have already established 55,100 tonnes of annual capacity across 26 critical APIs to reduce upstream dependence on China.

Put crudely: Ireland makes the world's most valuable medicines, and India makes the world's most medicines. A corridor that connects Irish biologics, sterile fill-finish and regulatory-grade quality systems with Indian API depth, formulation scale and cost-efficient science is not a marginal trade play. It is a structural completion of two value chains that are each missing what the other has.

Section 4: Where the Two Economies Are Exposed, and How the Corridor De-Risks Both

A corridor is only worth building if it solves a real problem for each side. It does, and the problems are close to mirror images.

Ireland's vulnerability is concentration. Over 60% of Irish pharma exports went to the United States in 2025, and the top three destinations together exceeded 80%. When Washington introduced tariffs on EU-produced pharmaceuticals in 2025 and floated further measures, the exposure became impossible to ignore, and the effect was visible in the data: Ireland's goods exports fell 29% in May 2026 as the pharma surplus narrowed. A single market's policy shift can move a double-digit share of the national export base. Diversification is no longer a strategic nicety; it is fiscal prudence. India, the world's third-largest pharmaceutical market by volume and one of its fastest-growing, is the most obvious large market where Irish biologics, diagnostics and high-value APIs are currently under-sold. Under EU-FTA tariff schedules, that gap becomes commercially addressable for the first time.

Europe's vulnerability is upstream dependence. According to the European Commission's Critical Medicines Alliance, China and India together account for roughly 55% of global API production, the EU around 30%, and the United States about 10%; by other Commission estimates up to 80% of APIs used in Europe are sourced from outside the bloc, with China alone supplying close to 45%. The Critical Medicines Act, backed by the European Parliament in January 2026, is the EU's structural response, aiming to diversify supply and rebuild European manufacturing of essential medicines. Here the interests of Ireland and India align rather than compete. India is itself pursuing a China-plus-one strategy, having built 55,100 tonnes of PLI-backed capacity across 26 critical APIs precisely to reduce its own dependence on Chinese key starting materials. An Ireland-India corridor lets Europe diversify its API sourcing toward a democratic, FDA-aligned, rule-of-law partner, while giving India a high-value, high-trust market to anchor its move up the quality curve. Supply-chain security for Europe and market access for India are, in this design, the same project.

The strategic synthesis is this: Ireland reduces its over-reliance on a single export market, Europe reduces its over-reliance on a single import source, and India converts scale into higher-value, higher-margin trade with a trusted partner. Three problems, one corridor.

Section 5: The Regulatory Bridge: An HPRA-CDSCO Compact

If tariffs are the EU's to set, regulation is where Ireland can lead, and it is the single highest-leverage item in this blueprint. The UK-India CETA's most consequential pharmaceutical provision was not a tariff line but the mutual recognition of Good Manufacturing Practice between the MHRA and CDSCO, which allows the two regulators to share audit reports and recognise each other's inspections, cutting duplicate facility audits and shortening batch clearance from a matter of months to days.

Ireland cannot replicate that unilaterally, because GMP mutual recognition at the EU border is a matter for the European Medicines Agency and the European Commission, not the HPRA alone. But Ireland occupies a uniquely influential seat. The Health Products Regulatory Authority is one of the EU's most respected medicines regulators, a leading rapporteur within the EMA system, and Ireland holds the EU Council Presidency as the EU-India relationship deepens. Ireland can therefore act as the architect and advocate of an EU-India regulatory cooperation track, rather than waiting for Brussels to prioritise it.

A phased regulatory bridge would run as follows. In the near term, a confidence-building arrangement between the HPRA and CDSCO on information sharing, joint inspection observation and aligned data requirements, using existing EMA-third-country cooperation mechanisms as the template. In the medium term, Irish leadership of a formal EU-India GMP dialogue aimed at a Mutual Recognition Agreement covering inspections of Indian facilities exporting to the EU, modelled on the EU-US and EU-Japan MRAs already in force. In the longer term, deeper convergence on pharmacovigilance, biosimilar comparability and quality data standards, so that a facility inspected once is accepted in both jurisdictions. Ireland should also address its own competitiveness in parallel: the Irish system's drug-approval and reimbursement timelines have drawn criticism, and a corridor that speeds Indian medicines to the EU border is only as good as the domestic pathway that follows.

Section 6: The Investment Corridor, Both Directions

Trade agreements move goods; investment builds the plants that make them. The corridor's physical footprint, the manufacturing sites, R&D centres and global capability centres, is where jobs and long-term value actually accrue, and it is fully contestable at national level.

Inbound to Ireland, the opportunity is to attract Indian pharmaceutical majors seeking an EU manufacturing and regulatory base. This is not hypothetical. Indian companies including Wockhardt, Sun Pharma and Reliance Life Sciences have held Irish operations for years; Wockhardt has run a site in Ireland since its 2006 acquisition of Pinewood Laboratories and is among the larger generic suppliers in the Irish market. As US and EU supply-chain security policies push Indian firms to establish trusted-jurisdiction production inside the tariff wall, Ireland's proposition—EU market access, EMA jurisdiction, an English-working-language environment, a common-law legal system and a deep life-sciences talent pool—is precisely what an Indian company scaling into Europe needs. The IDA should run a dedicated India life-sciences programme targeting biosimilar makers, CDMO and CRO groups, and API producers building EU-facing capacity under the Critical Medicines Act.

Outbound from Ireland, Irish and Ireland-based multinationals gain a clearer route into India's fast-growing market and its lower-cost manufacturing and clinical-research base, using FTA tariff schedules and, over time, the regulatory bridge. The Tech Mahindra acquisition of the Irish life-sciences services firm Perigord, and the long-standing presence of Irish groups such as ICON in India, show the two-way traffic already exists; the corridor formalises and scales it. The Joint Economic Commission should carry a standing life-sciences investment workstream tracking projects in both directions.

Section 7: The Research and Clinical-Trials Compact

The highest-value layer of any life-sciences relationship is not manufacturing but discovery, and this is where a corridor compounds over decades rather than quarters.

On research, Ireland and India already have a foundation to build on, including the cooperation agreement between Science Foundation Ireland's successor, Research Ireland, and Indian science bodies dating to 2006. A modern research compact would establish a joint Ireland-India life-sciences fund co-financed by Research Ireland and Indian agencies such as the Department of Biotechnology and the Biotechnology Industry Research Assistance Council, targeting antimicrobial resistance, vaccine platforms, biologics process science and affordable advanced therapies, areas where Irish depth in process research and Indian scale in development are genuinely complementary. The legislative momentum in the EU is also aligned, as seen during the Irish EU Council Presidency's €10B Biotech Act push, which is working to revitalize clinical research and biomanufacturing scale across Europe.

On clinical trials, the complementarity is even sharper. Ireland offers a high-quality, EU-regulated, English-speaking trial environment with an established base tracked on our Clinical Trials Ireland tracker; India offers very large, diverse and treatment-diverse patient populations and a rapidly professionalising trial infrastructure. Joint or sequential multi-centre trials across the two jurisdictions can accelerate recruitment and strengthen the evidence base for products intended for both markets. The professional-mobility provisions emerging from the FTA's Social Security Agreement framework matter here in the same way the UK-India Double Contributions Convention matters next door: they remove the double-social-security penalty that has made it costly to post principal investigators, data scientists and quality staff across borders for the duration of a trial.

Section 8: The People Corridor

None of this works without people, and the human infrastructure for an Ireland-India corridor is, unusually, already built.

The Indian community is one of the fastest-growing in Ireland and is disproportionately concentrated in exactly the sectors this corridor depends on. Healthcare professionals from India, Africa and other Asian countries account for roughly 23% of HSE nurses and midwives, and Indian doctors, pharmacists, engineers, data scientists and researchers are woven through Irish hospitals, universities and technology firms. There is a large and well-established Keralan community in particular. This diaspora is not a footnote to a trade relationship; it is the relationship's living tissue, the network of language, trust and professional familiarity along which a corridor actually runs.

A serious people corridor would therefore do three things. It would streamline talent mobility for life-sciences roles, using the FTA's mobility and social-security provisions to make it straightforward for Indian professionals to take fixed-term positions in Irish pharma and for Irish-based staff to spend time in Indian facilities. It would build education and skills links between Irish and Indian universities in pharmaceutical sciences, regulatory affairs, bioprocessing and quality, expanding the pipeline that Irish industry already struggles to fill, as our Irish Pharma Salary Guide 2026 shows in the persistent premium on skilled roles. And it would protect and value that community: the corridor's success depends on Ireland remaining a place where Indian professionals and their families feel welcome and safe, which makes social cohesion a matter of industrial strategy as much as of decency.

Section 9: The Numbers: A 2030 Scenario Model

To size the opportunity we built a transparent scenario model. It is deliberately simple and its assumptions are stated so readers can adjust them; it is Priya Life Science analysis, not an official forecast, and it should be read as illustrative rather than predictive.

We start from the established base: Ireland-India bilateral trade in goods and services of €17.7 billion in 2024, per the Central Statistics Office of Ireland, having grown roughly 60% between 2021 and 2023. We then model three trajectories to 2030.

The passive baseline assumes the relationship continues at its recent underlying growth without a deliberately built corridor, and the FTA's tariff effects phase in slowly. At an assumed 6% compound annual growth rate from 2024, bilateral trade reaches approximately €25 billion by 2030. The corridor scenario assumes the FTA enters force in 2027 as expected, and Ireland actively builds the four pillars—regulatory bridge, investment programme, research compact and people corridor. We model an assumed 9.8% CAGR, reflecting an incremental uplift from faster tariff pass-through, investment wins and services growth, reaching approximately €31 billion by 2030. The ambition scenario layers on major investment successes, an operational EU-India regulatory cooperation track and a step-change in services and clinical-trial activity, at an assumed 12% CAGR, approaching €35 billion by 2030.

Two sensitivities are worth naming. The estimate is sensitive to the FTA's entry-into-force date, currently targeted for the first half of 2027 but subject to EU ratification, and to the pace of the regulatory bridge, which is the hardest pillar to build and the one with the longest lead time. A corridor that secures the regulatory track early captures value faster; one that leaves regulation until last will underperform even the corridor line above.

Section 10: A Policy Blueprint

Turning this analysis into outcomes requires specific, ordered action. The following is a concrete agenda for the parties who can actually move it.

For the Irish Government and the Department of Foreign Affairs and Trade, the first-order move is to use the EU Council Presidency to champion swift, clean ratification of the EU-India FTA and to put EU-India regulatory cooperation on the agenda while Ireland holds the chair. The Joint Economic Commission should be convened with a life-sciences workstream as a standing item, and an India Life Sciences Strategy should be published naming targets, owners and timelines.

For the IDA, a dedicated India life-sciences investment programme should target biosimilar, CDMO, CRO and API companies seeking EU-facing capacity, with a value proposition built explicitly around EU market access, EMA jurisdiction and the Critical Medicines Act.

For the HPRA and, through it, the EMA, Ireland should initiate an HPRA-CDSCO confidence-building dialogue now and advocate within the EMA system for a formal EU-India GMP cooperation track leading toward a Mutual Recognition Agreement, using the EU-US and EU-Japan MRAs as templates.

For Research Ireland and Enterprise Ireland, a co-financed Ireland-India life-sciences research and innovation fund should be established, focused on antimicrobial resistance, vaccines, biologics process science and affordable advanced therapies, alongside a clinical-trials collaboration framework.

For Indian counterparts, the Ministry of Commerce, Pharmexcil and the pharmaceutical majors, Ireland should be positioned and promoted as the preferred EU entry point for Indian pharma investment, and Indian regulators should be encouraged to engage constructively with the EU regulatory track that Ireland is advocating.

Conclusion: A Corridor Is a Choice

The EU-India FTA is a Brussels achievement, and the UK-India CETA is a British one. Neither, by itself, does anything specific for Ireland. What happens next in the Ireland-India life-sciences relationship will be decided not by the treaty text but by whether Ireland chooses to build the regulatory bridges, investment pipelines, research compacts and talent frameworks that turn open markets into a working corridor.

The timing will not repeat. The FTA is moving toward force, Ireland holds the EU Council Presidency at the decisive moment, Europe is actively seeking to diversify its API supply, India is actively moving up the value chain, and a deep, skilled diaspora already connects the two countries. Ireland has, at once, a market-diversification imperative, a supply-security tailwind, an institutional platform and a human network. The window is open. A corridor is a choice, and this is the moment to make it.

Frequently Asked Questions (FAQ)